GNI Group Ltd. 2160
TSE · Japan · Health Technology
¥3,305.00+45.00 (+1.38%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Japan-Originated Global Biopharma Company Founded in 2001 Enters Its “Second Founding Phase”TOKYO, July 01, 2026 (GLOBE NEWSWIRE) -- GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. As a result, Ayumi Pharmaceutical Holdings Co., Ltd. and its subsidiary, Ayumi Pharmaceutical Co., Ltd. (“Ayumi Pharmaceutical”), have become wholly owned subsidi
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic AreasTOKYO, June 07, 2026 (GLOBE NEWSWIRE) -- GNI Group Co., Ltd. (TSE: 2160) today announced that it has entered into an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. The transaction values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion and will make the company a wholly owned
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.